Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02168777
Title Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Bayer
Indications

lung non-small cell carcinoma

colorectal cancer

breast cancer

Advanced Solid Tumor

Therapies

Refametinib + Regorafenib

Refametinib

Age Groups: adult
Covered Countries USA


No variant requirements are available.